Sapient Capital LLC Has $209,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Sapient Capital LLC trimmed its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 57.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,358 shares of the company's stock after selling 4,546 shares during the quarter. Sapient Capital LLC's holdings in TransMedics Group were worth $209,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Harbour Capital Advisors LLC lifted its position in shares of TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company's stock valued at $760,000 after buying an additional 81 shares during the last quarter. Venturi Wealth Management LLC lifted its position in shares of TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company's stock valued at $136,000 after buying an additional 219 shares during the last quarter. National Bank of Canada FI lifted its position in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after buying an additional 262 shares during the last quarter. Quarry LP lifted its position in shares of TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company's stock valued at $58,000 after buying an additional 312 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock valued at $76,000 after buying an additional 316 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Remove Ads

TransMedics Group Price Performance

TransMedics Group stock traded up $0.96 during trading hours on Friday, reaching $72.18. 1,013,799 shares of the stock were exchanged, compared to its average volume of 2,287,730. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a market cap of $2.42 billion, a P/E ratio of 76.79 and a beta of 2.12. The stock has a 50 day moving average of $65.87 and a two-hundred day moving average of $106.53.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TMDX. Oppenheimer reaffirmed an "outperform" rating and issued a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Wednesday, February 5th. Piper Sandler decreased their price objective on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a report on Wednesday, December 11th. Canaccord Genuity Group dropped their target price on TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a report on Wednesday, November 20th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.